Closely held ReAlta Life Sciences has appointed immunologist Laurie Glimcher, MD, to its board of directors (BOD), effective immediately.
Dr. Glimcher, widely renown for her work in cancer research, brings more than 35 years of leadership experience in world-class institutions. Currently the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School, she has served as president and CEO of the Dana-Farber Cancer Institute from 2016 to 2024 where she continues to oversee her lab focused on the molecular pathways that regulate the immune system.
In a statement, David Marek, CEO of ReAlta, said, “We are honored to welcome Laurie to ReAlta’s Board of Directors. She is a trailblazer in immunology and cancer research, and her expertise and understanding of drug development innovation at the highest levels will be invaluable as we continue advancing our clinical pipeline across diseases in immunology and inflammation.”
Dr. Glimcher commented, “ReAlta’s unique approach to modulating the immune system through its dual-targeting peptide platform resonates with my past and ongoing research in immune responses and cancer immunotherapy. I look forward to working with the management team and fellow board members to help advance ReAlta’s mission to develop transformative therapies for patients with severe inflammatory diseases.”
